NCT00286429 - Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes. | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin and insulin

Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.

DRUG

Alogliptin and insulin

Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.

DRUG

Insulin

Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.

Trial Locations (60)

Unknown

Phoenix

Anaheim

Artesia

Fresno

Mission Viejo

Northridge

Orange

San Diego

Tustin

Walnut Creek

Denver

Cocoa Beach

Longwood

New Port Richey

Ocala

Saint Cloud

Tampa

Lawrenceville

Honolulu

Avon

Evansville

Lafayette

St Louis

Omaha

Berlin

Burlington

Charlotte

Hickory

Morehead City

Pinehurst

Winston-Salem

Cincinnati

Tulsa

Medford

Lansdale

Charleston

Columbia

Simpsonville

Cookeville

Corpus Christi

Dallas

San Antonio

Temple

Texarkana

Burlington

Multiple Cities